X @The Economist

Being first did not guarantee success for Novo Nordisk. But being early may yet pay off for both the Danish pharma giant and its American arch-nemesis https://t.co/uibIPykb9mIllustration: Brett Ryder https://t.co/PfiU0y8gOu ...